Ipsen Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Ipsen Bundle
What is included in the product
Detailed Word Document
Ipsen BCG Matrix analysis for strategic product portfolio decisions.
Customizable Excel Spreadsheet
Export-ready design to instantly integrate your BCG analysis into presentations and reports.
Full Transparency, Always
Ipsen BCG Matrix
The displayed preview is identical to the BCG Matrix you'll receive post-purchase. This means a ready-to-use, comprehensive analysis without any demo content or watermarks.
BCG Matrix Template
Visual. Strategic. Downloadable.
The Ipsen BCG Matrix helps analyze the company's portfolio, categorizing products by market share and growth rate. This framework identifies Stars, Cash Cows, Dogs, and Question Marks. Understanding these positions reveals strategic needs, from investment to divestiture. A quick preview shows the basics.
Get instant access to the full BCG Matrix and discover which products are market leaders, which are draining resources, and where to allocate capital next. Purchase now for a ready-to-use strategic tool.
Stars
Cabometyx (oncology)
Cabometyx, an oncology drug, is a star within Ipsen's portfolio. It holds a substantial market share and shows consistent growth. In 2024, Cabometyx generated approximately $1.7 billion in sales. Further trials and potential regulatory approvals, especially in Europe, will likely boost its market position.
Dysport (neuroscience)
Dysport, a neurotoxin, is a star product in Ipsen's portfolio. In 2024, the global aesthetics market, where Dysport is a key player, is valued at billions, with neurotoxins like Dysport showing strong growth. Ipsen's strategic focus on neuroscience, including Dysport, has yielded revenue growth, driven by expansion and demand. Continued investment in Dysport is essential for maintaining its market leadership.
Bylvay (rare diseases)
Bylvay, used for pruritus in PFIC and ALGS, rapidly grows sales, becoming central to Ipsen's rare disease franchise. In 2024, Bylvay's revenue reached €376 million, up significantly. Expansion into biliary atresia could elevate its standing. Ipsen's Albireo acquisition underscores Bylvay's strategic value.
Onivyde (oncology)
Onivyde, a key asset for Ipsen, is approved for metastatic pancreatic ductal adenocarcinoma (mPDAC) treatment. Its U.S. approvals and launches are vital for growth. Commercial success and market expansion are crucial. In 2023, Onivyde's global sales were around €400 million.
- U.S. market launch and regulatory approvals.
- Focus on commercial execution strategies.
- Expansion into new geographical markets.
- Onivyde's global sales in 2023 were approximately €400 million.
Iqirvo (rare diseases)
Iqirvo, approved for second-line primary biliary cholangitis (PBC), is boosting Ipsen's rare disease portfolio. It is rapidly gaining market share. Phase 2 PSC data may broaden its reach. Sustained growth relies on global rollout and investment.
- 2023 sales of Ipsen's rare disease portfolio reached €1.1 billion.
- Iqirvo's market share is growing, though specific figures are proprietary.
- Phase 2 PSC data is anticipated in the near future, potentially expanding the addressable market.
- Continued investment in global rollout is crucial for Iqirvo's long-term success.
Top-Performing Products Fueling Growth
Ipsen's "Stars" include high-growth products with significant market share. Cabometyx, Dysport, Bylvay, Onivyde, and Iqirvo drive revenue, with 2024 sales data highlighting their importance. Continuous investment supports their market leadership and expansion.
| Product | 2024 Revenue (Approx.) | Key Strategy |
|---|---|---|
| Cabometyx | $1.7B | Expand trials & approvals |
| Dysport | Growing | Focus on neuroscience |
| Bylvay | €376M | Expand indications |
| Onivyde | €400M (2023) | U.S. launch & expansion |
| Iqirvo | Growing | Global rollout |
Cash Cows
Somatuline (oncology)
Somatuline, a key oncology product for Ipsen, treats neuroendocrine tumors and is a major revenue source. Despite growing generic competition, it still provides significant cash flow. In 2024, Somatuline sales were approximately €700 million. Ipsen should focus on efficient production and distribution.
Decapeptyl (oncology)
Decapeptyl, an off-patent oncology drug, holds a leading market position. It offers a stable revenue stream, even without high growth. Ipsen should use its market strength and sales force to retain its share. In 2024, Decapeptyl's sales contributed significantly to Ipsen's revenue.
Smecta (consumer healthcare)
Smecta, within Ipsen's consumer healthcare, is a steady revenue source. Its brand recognition and distribution ensure stability. Maximizing profitability involves efficient management. In 2024, Smecta's sales showed consistent performance, contributing to Ipsen's overall financial health.
Forlax (consumer healthcare)
Forlax, a consumer healthcare product by Ipsen, is a cash cow because of its strong market presence. It generates steady income, requiring minimal new investment. Focusing on efficient supply chains and distribution is key for maximizing cash flow. In 2024, Ipsen's consumer healthcare sales are expected to be strong.
- Mature product with stable sales.
- Requires little additional investment.
- Focus on optimizing supply and distribution.
- Generates consistent cash flow.
Fortrans (consumer healthcare)
Fortrans, a consumer healthcare product within Ipsen's portfolio, exemplifies a cash cow, generating steady revenue with minimal investment. Ipsen can maintain profitability by focusing on operational efficiency and utilizing established distribution channels. Aggressive marketing or expansion isn't necessary for Fortrans. In 2024, the consumer healthcare segment contributed significantly to Ipsen's revenue.
- Steady revenue streams with low investment needs.
- Focus on operational efficiencies to maximize profits.
- Leverage existing distribution networks for sales.
- Limited need for aggressive marketing or expansion.
Ipsen's Mature Products: Steady Revenue Streams
Ipsen's cash cows, like Somatuline, Decapeptyl, Smecta, Forlax, and Fortrans, are mature products. They generate stable, consistent revenue. These require minimal new investment.
| Product | 2024 Sales (approx.) | Strategy |
|---|---|---|
| Somatuline | €700M | Efficient Production & Distribution |
| Decapeptyl | Significant Contribution | Market Strength & Sales Force |
| Smecta | Consistent | Efficient Management |
Dogs
Increlex (rare diseases)
Increlex, once in Ipsen's rare disease unit, was sold to Eton Pharmaceuticals. This move likely stemmed from underperformance or a shift in Ipsen's strategy. The divestiture was a smart move to reallocate resources. In 2024, Ipsen's focus is on core areas, as seen in its financial reports.
Tanakan (consumer healthcare)
Tanakan, a consumer healthcare product for Ipsen, could be a "dog" if its sales and market share are low. In 2023, Ipsen's total revenue was €3.03 billion, with consumer healthcare contributing a smaller portion. If Tanakan's sales are minimal, Ipsen might consider divesting or discontinuing it. Turnaround plans are often ineffective for "dogs."
Eziclen (consumer healthcare)
Eziclen, within Ipsen's portfolio, would be categorized as a "Dog" if it has low market share in a slow-growth market. Its contribution to overall revenue is minimal, and it struggles to generate substantial profits. In 2024, if Eziclen's sales continue to decline while facing strong competition, it would reinforce its "Dog" status. Ipsen might consider selling it to free up resources.
Sohonos (rare disease - FOP)
Sohonos, aimed at treating Fibrodysplasia Ossificans Progressiva (FOP), faced challenges. In 2024, Ipsen reported a €279 million impairment loss for Sohonos. This loss, about €2.33 per share, was due to lower-than-expected sales. Consequently, Sohonos fits the 'Dog' category in the BCG Matrix.
- Sohonos targeted FOP treatment.
- 2024 saw a €279 million impairment.
- The loss reflected poor sales.
- Classified as a 'Dog' in BCG.
Palovarotene (rare disease - FOP)
Palovarotene, aimed at fibrodysplasia ossificans progressiva (FOP), presented a significant setback for Ipsen. The FDA's clinical hold on the drug led to financial losses. Given the challenges and lack of progress, it fits the "Dog" category in the BCG matrix.
- Clinical hold by FDA impacted the drug.
- The drug faced financial losses.
- It is in the "Dog" category.
Ipsen's "Dogs": Financial Strain and Setbacks
Ipsen's "Dogs" struggle with low market share and growth. These products drain resources without significant returns. In 2024, Sohonos faced a €279M impairment, highlighting financial strain. Palovarotene also falls into this category, facing setbacks and losses.
| Product | Category | 2024 Status |
|---|---|---|
| Sohonos | Dog | €279M Impairment |
| Palovarotene | Dog | Clinical Hold |
| Tanakan | Dog (Potential) | Low Sales |
| Eziclen | Dog | Declining Sales |
Question Marks
Fidrisertib (rare diseases)
Fidrisertib, targeting fibrodysplasia ossificans progressiva (FOP), is in a pivotal Phase IIb trial, FALKON, with 2025 readout. Its high-growth potential is offset by market share uncertainty. Ipsen faces crucial investment or divestiture decisions based on FALKON's results. Ipsen's 2024 R&D spending was €1.1 billion, highlighting the stakes.
Tovorafenib (oncology)
Tovorafenib, an oral RAF inhibitor, targets pediatric low-grade glioma. It's in the "Question Mark" quadrant of Ipsen's BCG Matrix due to its high growth potential but low market share. Ipsen's EMA submission in 2025 is crucial. Market size for such treatments is projected to reach $1.5 billion by 2028. Ipsen must decide on investment or divestiture based on its market share progress.
Long-Acting Neurotoxin (LANT) (neuroscience)
Long-Acting Neurotoxin (LANT) is a potential game-changer in aesthetics, a market valued at $16.5 billion in 2024. Currently, LANT's market share is low, as the product is in the proof-of-concept data readout phase, specifically the LANTIC trial. Ipsen faces a pivotal decision based on the data: significant investment or asset sale. The aesthetics market's growth, projected to reach $26.4 billion by 2029, makes this decision critical.
IPN01194 (oncology)
IPN01194, Ipsen's ERK inhibitor, is a "star" in the BCG Matrix due to its potential in oncology. It's in Phase I/IIa trials for advanced solid tumors, indicating high growth potential. However, its market share is uncertain at this stage, making it a "question mark." Ipsen faces a critical decision on whether to invest further or seek a partnership.
- Phase I/IIa trials are expensive, with costs ranging from $5M to $20M.
- Success rates for oncology drugs in Phase I/II are about 30%.
- The global oncology market was valued at $200B in 2024.
- Ipsen's R&D spending in 2023 was roughly 25% of its revenue.
STRO-003 (oncology)
STRO-003, an antibody-drug conjugate (ADC) targeting the ROR1 tumor antigen, is in late pre-clinical development. Ipsen holds exclusive worldwide rights. Its placement in the BCG matrix requires evaluation of its potential for investment. Ipsen must decide on clinical trials or a potential sale based on early results.
- STRO-003 targets ROR1, a protein often found on cancer cells.
- Ipsen acquired the rights, indicating a strategic move into oncology.
- The decision involves assessing clinical trial investment versus divestiture.
- Early results are crucial for determining STRO-003's future within Ipsen's portfolio.
Ipsen's High-Growth, Low-Share Products: Invest or Divest?
Question Marks represent products with high growth potential but low market share within Ipsen's portfolio, as of 2024. Ipsen must decide whether to invest further or divest these assets based on clinical trial results, such as those for tovorafenib with an EMA submission in 2025. These products often require significant investment in R&D, with costs ranging from $5M to $20M in Phase I/IIa trials, and face uncertainty due to early-stage development.
| Product | Status | Decision |
|---|---|---|
| Tovorafenib | EMA submission in 2025 | Invest/Divest based on market share |
| LANT | Proof-of-concept | Invest or asset sale |
| IPN01194 | Phase I/IIa trials | Further investment or partnership |
BCG Matrix Data Sources
Our BCG Matrix leverages diverse financial datasets, including market share estimates and industry growth rates from reliable market research and expert reports.
